Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totalling 4,450,000 shares, an increase of 22.9% from the July 15th total of 3,620,000 shares. Based on an average trading volume of 315,700 shares, the short-interest ratio is currently 14.1 days.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on RVPH shares. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Reviva Pharmaceuticals in a research note on Thursday, July 11th. Maxim Group restated a “hold” rating on shares of Reviva Pharmaceuticals in a report on Friday. Finally, Benchmark restated a “speculative buy” rating and set a $17.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, May 28th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $14.33.
View Our Latest Analysis on Reviva Pharmaceuticals
Institutional Inflows and Outflows
Reviva Pharmaceuticals Stock Down 6.0 %
NASDAQ RVPH traded down $0.04 during trading hours on Friday, hitting $0.64. 549,762 shares of the company were exchanged, compared to its average volume of 304,029. The company has a 50 day moving average of $1.14 and a two-hundred day moving average of $2.42. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $6.80. The firm has a market cap of $17.98 million, a price-to-earnings ratio of -0.41 and a beta of -0.09.
Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. On average, equities research analysts predict that Reviva Pharmaceuticals will post -0.98 EPS for the current year.
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.
Featured Articles
- Five stocks we like better than Reviva Pharmaceuticals
- Investing in the High PE Growth Stocks
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is a Dividend King?
- MarketBeat Week in Review – 8/12 – 8/16
- What Are Dividend Achievers? An Introduction
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.